EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Janet E McElhaney, Andrew E Simor, Shelly McNeil, Gerald N Predy

Influenza Research and Treatment · 2011

DOI: 10.1155/2011/759051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza Research and Treatment, 2011. Verfasst von Janet E McElhaney und 3 weiteren Autor:innen. Beteiligte Einrichtung: UBC Gerontology and Diabetes Research, 186-828 West 10th Avenue, Vancouver, BC, Canada V5Z 1L8. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Afexa Life Sciences Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CVT-E002 (a proprietary extract) was found to be effective in the prevention of upper respiratory infections (URIs) in healthy adults, and institutionalized and community-dwelling seniors. A multicenter, randomized, double-blind, placebo-controlled trial was carried out to determine effects of CVT-E002 in the prevention of URIs in influenza-vaccinated community-dwelling adults. 783 community-dwelling adults were randomized to receive placebo, 400 mg or 800 mg treatment/d (1 : 1 : 1) for 6 months. Primary analysis on the incidence of laboratory-confirmed-clinical URIs (LCCUs), including influenza A and B, was performed on those receiving at least one dose. Secondary analysis was performed on study completers and included incidence, severity, and duration of URIs meeting a Jackson-based criteria and safety of CVT-E002. The incidence of LCCUs in the ITT group was 5.5%, 5.2%, and 4.6% in the placebo, 400 mg and 800 mg groups, respectively ( P = 0.89 ). Jackson-confirmed URIs were significantly lower in the treated groups ( P < 0.04 ). CVT-E002 supplementation reduced the severity and duration of Jackson-confirmed URIs. The results indicate that CVT-E002 can be safely used by similar groups and may prevent symptoms of URIs; larger sample size is warranted.

Autor:innen und Institutionen

  • UBC Gerontology and Diabetes Research, 186-828 West 10th Avenue, Vancouver, BC, Canada V5Z 1L8.

Förderung

  • Afexa Life Sciences Inc.

Zitieren

APA

McElhaney, J. E., Simor, A. E., McNeil, S., & Predy, G. N. (2011). Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial. Influenza Research and Treatment. https://doi.org/10.1155/2011/759051

Vancouver

McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial. Influenza Research and Treatment. 2011. doi:10.1155/2011/759051

BibTeX
@article{McElhaney2011,
  author = {McElhaney, Janet E and Simor, Andrew E and McNeil, Shelly and Predy, Gerald N},
  title = {Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial},
  journal = {Influenza Research and Treatment},
  year = {2011},
  doi = {10.1155/2011/759051}
}
Kostenlos starten →